Lisa Meier McShane

49PUBLICATIONS
320CO-AUTHORS
Molecular targetsPredictive and prognostic markersLiquid biopsiesGene expression (incl. microarray and other genome-wide approaches)Cancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (49)

|Aug 11, 2026
ERK1/2 Inhibitor Ulixertinib in Pan-cancer Patients with BRAF Fusions or Non-V600E/K Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1L.

|Aug 07, 2026
Associations of Age With Tumor Genomic Characteristics in Relapsed/Refractory Cancers Interrogated With the NCI-MATCH Trial Targeted Gene Panel Assay.

|Jun 17, 2026
Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I.

|Feb 20, 2026
Larotrectinib in Patients With Tumors With NTRK Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-Z1E.

Neal Akhave, Zihe Song, David S Hong

|Jan 20, 2026
Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2.

Niamh Coleman, Zihan Wei, A John Iafrate

|Jan 14, 2026
Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol H.

April K S Salama, Victoria Wang, Erin R Macrae

Pageof 9

Frequent Collaborators

28 joint publications

David R Patton

27 joint publications

Robert J Gray

27 joint publications

Keith T Flaherty

26 joint publications

Lawrence V Rubinstein